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Abstract
Background: Patients with rheumatoid arthritis (RA) have an increased risk for cardiovascular disease (CVD) with
poor parasympathetic function being implicated as an underlying factor. Factors related to parasympathetic
function, commonly assessed by heart rate recovery (HRR) following maximal exercise, are currently not known in
RA. We aimed to explore the association between HRR with CVD risk factors, inflammatory markers, and wellbeing
in patients with RA.
Methods: Ninety-six RA patients (54.4 ± 12.6 years, 68 % women) completed a treadmill exercise test, during which
heart rate (HR) was monitored. HRR1 and HRR2 were defined as the absolute change from HR peak to HRR
1 min post HR peak and 2 min post HR peak, respectively. Cardiorespiratory fitness, CVD risk factors, and
serological markers of inflammation were measured in all patients. The Framingham Risk Score (FRS) was used
as an assessment of global risk for CVD events, and wellbeing was assessed by questionnaires.
Results: Mean HRR1 and HRR2 were 29.1 ± 13.2 bpm and 46.4 ± 15.3 bpm, respectively. CVD risk factors as
well as most inflammatory markers and measures of wellbeing were inversely correlated with HRR1 and
HRR2. Multivariate regression analyses revealed that 27.9 % of the variance in HRR1 and 37.9 % of the
variance in HRR2 was explained collectively by CVD risk factors, measures of inflammation, and wellbeing
(p = 0.009, p = 0.001 respectively), however no individual measure was independently associated with HRR1
or HRR2.
Conclusion: Parasympathetic activation was associated with overall CVD risk, arthritis-related burden and
wellbeing in patients with RA.
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Background
Rheumatoid arthritis (RA) is an autoimmune disease
characterized by chronic systemic inflammation affecting
approximately 1 % of the general population [1]. The
main symptoms are pain, stiffness and swelling of joints.
However, there are also extra-articular aspects in RA,
such as an increased risk for cardiovascular disease
(CVD), which causes more than 40 % of the deaths in
RA [2]. Although the mechanisms for the increased risk
for developing CVD in RA remain to be elucidated, sev-
eral risk factors for CVD are prevalent in RA, such as
hypertension [3] dyslipidemia [4], physical inactivity [5],
inflammation [6]. This increased prevalence of CVD risk
factors has been associated with abnormalities in vascu-
lar function and morphology [7], which could lead to
CVD and even CVD-related death [8]. More recently, in
a systematic review by Adlan et al. [9], autonomic dys-
function has been suggested as another factor which
contributes to the CVD death risk in RA.
The autonomic nervous system (ANS) is divided into
the sympathetic and the parasympathetic system, which,
in a healthy state, work together to maintain cardiovas-
cular autonomic balance. Autonomic dysfunction, an in-
creased activity of the sympathetic tone and less
parasympathetic tone at rest [10], has been associated
with increased risk of CVD [11] and all-cause mortality
[12]. Inflammation has been related to autonomic dys-
function in clinical [13], and healthy populations [14].
However, little is known about the factors that contrib-
ute to autonomic dysfunction in a population with a
high long-term inflammatory burden, such as patients
with RA [15].
A common method to assess autonomic function, and
in particular parasympathetic tone, is heart rate recovery
(HRR). The rapid fall in heart rate immediately following
an exercise tolerance test (ETT) is suggested to repre-
sent reactivation of the parasympathetic tone [16]. HRR
is a predictor of CVD and all-cause mortality [16], and
has been associated with inflammation levels in a
healthy population [14]. HRR is commonly assessed one
or two minutes post exercise, which is thought to reflect
the parasympathetic activity and withdrawal of sympa-
thetic activity, respectively [17]. Even though autonomic
function has been explored in RA using different
methods [15, 18–40], to our knowledge, HRR following
exercise has recently been investigated in a pilot study
involving RA and Juvenile idiopathic RA [41]. However,
the study was looking at the improvement post exercise
intervention and there was no investigation over factors
associated with HRR. Therefore, the aim of this cross-
sectional study was to assess HRR post ETT and explore
factors associated with HRR in RA. It was hypothesized
that HRR is associated with markers of CVD risk, as well
as markers of inflammation and wellbeing.
Methods
Study population
Ninety-six RA patients (fulfilling the revised American
College of Rheumatology criteria [42]), were recruited
from outpatient clinics of the Dudley Group NHS Foun-
dation Trust, UK from October 2011 to 2014 to partici-
pate in an exercise intervention study (Trial registration
number: ISRCTN04121489). Exclusion criteria were:
fibromyalgia, recent joint surgery (in the preceding six
months), comorbidity incompatible with exercise as per
American College of Sports Medicine (ACSM) guide-
lines [43], atrial fibrillation, and established CVD. Ethical
approval was obtained by the National Research Ethics
Service and all patients provided written informed con-
sent prior to participation.
Protocol
Participants were invited to visit the research laboratory
on two different occasions. During visit one, a fasted
blood sample was taken and questionnaires were given.
During visit two, brachial blood pressure was taken
using electronic sphygmomanometer (Datascope Accu-
tor, Mahwah, NJ, USA) while the patient was seated.
Height was measured to the nearest 0.5 cm using a
standard height measure (Seca 214 Road Rod), weight
and BMI were measured using a Tanita BC 418 MA
Segmental Body Composition Analyser (Tanita Corpor-
ation, Tokyo, Japan). Subsequently, the patients were fit-
ted with an appropriate size mask to cover the nose and
mouth securely for the purpose of inspired and expired
gas analysis, and electrocardiography (ECG) (12-channel
ECG custo cardio 200, custo med, Liepzig, Germany)
electrodes were attached. Resting heart rate and volumes
of O2 consumption were recorded for two minutes while
seated, followed by an ETT and six minutes post ETT
recovery period.
Exercise Tolerance Test (ETT)
ETT was performed on a treadmill (HP Cosmos Mercury,
Nussdoerf-Traunstien, Germany). All patients performed
an individualized treadmill ETT which was modified ac-
cording to their fitness and physical abilities [44]. The
starting speed of the test was set based on the patient’s
preference (approximately three mph) and 0 % inclination.
Thereafter, the speed was gradually increased until a max-
imum brisk walking was reached, again based on the
patient’s ability.
After two minutes warming up at the preferred speed,
the test started. The inclination increased by one percent
every minute while keeping the speed constant. Breath
by breath gas analyses (Metalyzer 3B, Cortex, Liepzig,
Germany) were recorded throughout the exercise task,
which was used to calculate peak volume of O2 uptake
(VO2 peak). ECG was recorded throughout the exercise
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task and recovery period. The test was terminated if
patients reached volitional exhaustion, or any of the rela-
tive or absolute contraindications of ACSM’s guidelines
[43] were met. Following the termination of the test,
patients were asked to rest on a chair for a minimum of
six minutes recovery while blood pressure was measured
every two minutes.
Outcome measures
Heart rate recovery
HRR was measured at 1 and 2 min following peak heart
rate during exercise. Heart rate recovery 1 min (HRR1)
was defined as the absolute change from peak heart rate
to heart rate 1 min post peak heart rate (HRR1 = peak
heart rate – heart rate at 1 min post peak heart rate).
Similarly, heart rate recovery 2 min (HRR2) was calculated
as the absolute change from peak heart rate to heart rate
2 min post peak heart rate. Peak heart rate was identified
as the maximum heart rate during the exercise protocol.
VO2 peak
Aerobic capacity (VO2 peak) was measured during
treadmill ETT via a breath by breath gas analyser. The
inspired and expired gases data from the analyser were
averaged every 2 s. To avoid spikes and fluctuations of
the VO2 ml/min readings, these data were smoothened
by taking the average of VO2 every 28 s (taking the aver-
age of 14 readings of VO2 ml/min). VO2 peak was
defined as the highest VO2 during the test and was
expressed as ml/min/kg.
Serological assessments
The blood samples were analysed for serological risk fac-
tors for CVD: total cholesterol, high density lipoprotein
(HDL), low density lipoprotein (LDL), and triglycerides.
Homeostasis models assessment (HOMA) was utilized to
assess insulin resistance [45]. Inflammatory markers were
assessed including erythrocyte sedimentation rate (ESR),
high sensitivity C-reactive protein (hsCRP), fibrinogen, and
white blood cells (WBC). Analyses were carried out using
routine laboratory procedures in the hospital’s laboratory.
Global cardiovascular risk
In order to measure the probability of occurrence of car-
diovascular events within 10 years period, the Framing-
ham risk score was utilized [46].
Measures of wellbeing
Functional ability, psychological and general wellbeing were
assessed using health assessment questionnaire (HAQ)
[47], hospital anxiety and depression scale (HADS) [48],
subjective vitality scale [49], multidimensional assessment
of fatigue (MAF) [50], and the European quality of life
questionnaire (EuroQol) [51].
Statistical analysis
Statistical analysis was performed using SPSS20 (Chicago,
IL, USA). Kolmogorov-Smirnov test was used to test the
normality of all variables. Log-transformation was per-
formed for non-normally distributed variables (BMI,
triglycerides, LDL, hsCRP, ESR, HOMA, FRS, HADS
depression, EuroQol). All normally distributed variables
were presented as mean and standard deviation, whereas,
non-normally distributed variables were presented as
median and interquartile range. To assess the relationship
between HRR at both time points and other normally dis-
tributed variables, bivariate correlation (correcting for
gender as a possible confounder) using Pearsons moment.
Bivariate correlation was performed on normally distrib-
uted variables and after log transformation for the skewed
variables. To assess factors associated with HRR at both
time points, two multivariate linear regression were used
using enter method (correcting for gender) where HRR
(HRR1 and HRR2 separately) was the dependent variable,
while the independent variables were all the variables that
came out significantly associated with HRR1 and HRR2
separately in our correlation analysis. The level of signifi-
cance for all analyses was set at .05.
Results
Patient characteristics
Demographic characteristics as well as CVD risk, markers
of inflammation and wellbeing of the 96 RA patients (66
female, 30 male, disease duration 7.9 ± 9.1 years) are pre-
sented in Table 1. The most common comorbidities were
hypertension (33 %) and diabetes (8 %), and 9 % were
current smokers whereas 44 % of the patients were previ-
ous smokers. The types of medication used included:
Methotrexate (74 %), other non-biologic disease modifying
anti-rheumatic drugs (DMARDs) (52 %), anti-tumor ne-
crosis factor (12 %), other biologic DMARDs (3 %), pred-
nisolone (16 %), non-steroidal anti-inflammatory drug
(35 %), analgesics (37 %), cholesterol-lowering (27 %), and
anti-hypertensive (24 %). Patients were requested to main-
tain their course of treatment during the study. The results
from the exercise tests, including HRR1 and HRR2, are
presented in Table 2. On average, the overall fitness level of
the participants was low as indicated by their mean VO2
max 20.6 ± 5.1 ml/min/kg [52].
Correlations
Correlational analyses were conducted to explore the as-
sociations between HRR and risk factors for CVD and
wellbeing. With regards to CVD risk factors, results re-
vealed that HRR1 and HRR2 were inversely associated
with age and triglycerides, whereas resting SBP was only
inversely associated with HRR2 (Table 3). HRR2 was in-
versely associated with HOMA (r (87) = − .27, p = .009).
VO2 peak was positively associated with HRR1 and
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HRR2 (r (93) = .33, p = .001 and r (93) = .41, p < .001, re-
spectively). HRR1 and HRR2 were both inversely related
to FRS. WBC, Fibrinogen, hsCRP, and ESR were all in-
versely associated with HRR1, and, albeit somewhat
weaker, with HRR2 with the exception of CRP (Table 3).
With regards to measures of wellbeing, EuroQol and vital-
ity were positively associated with HRR1 (r (90) = .26,
p = .01 and r (88) = .30, p = .004), respectively, whereas,
only vitality was significantly associated with HRR2
(r (88) = .21, p = 0.05). Additional non-parametric correl-
ational analyses (Spearman correlation) were conducted
between HRR and those variables which were not nor-
mally distributed. These analyses revealed similar associa-
tions as the Pearsons correlations reported on the log-
transformed data (data not reported).
Linear regression
In order to identify if the variables were independently
associated with HRR, all variables which were signifi-
cantly correlated with HRR were subsequently entered
in multivariate linear regression analyses (see Table 4). A
model (based on the correlated variables in the univari-
ate analyses) which included age, triglycerides, VO2
Table 1 Demographic characteristics, CVD risk, inflammatory
markers, and measures of wellbeing
Characteristics Value
Cardiovascular risk factors
Age (years) 54.4 ± 12.6
Height (m) 1.7 ± .09
Weight (Kg) 79.3 ± 18.5
BMI (Kg/m2) 27.8 (23.9–31)
Heart rate rest (bpm) 79.7 ± 12.5
Resting SBP (mmHg) 134.2 ± 17
Resting DBP (mmHg) 81 ± 9.7
Total cholesterol (mmol/L) 5.1 ± 1.05
Triglycerides (mmol/L) 1.1 (0.8–1.4)
HDL (mmol/L) 1.4 ± 0.38
LDL (mmol/L) 3.1 (2.5–3.6)
HOMA 1.5 (0.94–2.05)
Framingham risk score 7 (4–13)
Inflammatory markers
WBC (109/ litre) 6.8 ± 2.4
Fibrinogen (g/L) 4.7 ± 1.1
HsCRP (mg/L) 4.6 (1.6–8.8)
ESR (mm/hr) 10 (5–21.5)
Wellbeing
Vitality 4.1 ± 1.6
HADS anxiety 6.7 ± 4.2
HADS depression 4 (2–7)
Global Fatigue 25.8 ± 11.8
EuroQol 0.7 (0.6–0.8)
Values are presented as means ± standard deviation, or median (25th to 75th
percentile values) as appropriate. BMI, body mass index; SBP, systolic blood
pressure; DBP, diastolic blood pressure; HDL, high density lipoprotein; LDL, low
density lipoprotein; WBC, white blood cells; HsCRP, high sensitivity C-reactive
protein; ESR, erythrocyte sedimentation rate; HOMA, homeostasis model
assessment insulin resistance; Vitality, score ranges 0 (low vitality) – 6 (high
vitality); HADS, hospital anxiety and depression scale (0–21); Global fatigue,
score ranges from 0 (no fatigue) – 50 (severe fatigue) EuroQol, European
assessment for quality of life
Table 2 Exercise related variables
Variable Value (Mean ± SD)
Heart rate peak (bpm) 153.4 ± 19.7
VO2 peak (ml/min/kg) 20.6 ± 5.1
RER (VCO2/VO2) 1.2 ± 0.1
HRR1 (bpm) 29.1 ± 13.2
HRR2 (bpm) 46.4 ± 15.3
VO2 peak, highest volume of oxygen; RER, respiratory exchange ratio; HRR1,
the difference between HR peak and heart rate 1 min post HR peak; HRR2,
the difference between HR peak and heart rate 2 min post HR peak
Table 3 Correlation of HRR1 and HRR2 with CVD risk,
inflammatory markers, and wellbeing
HRR1 HRR2
Variable r p r p
Cardiovascular risk factors
Age −.27 .006 −.44 <.001
BMI −.15 .14 −.08 .43
Resting SBP −.18 .08 −.28 .005
Resting DBP −.09 .38 −.10 .33
Triglycerides −.31 .003 −.27 .008
HOMA −.14 .18 −.27 .009
VO2 peak .33 .001 .41 <.001
Framingham risk score −.29 .005 −.45 <.001
Inflammatory markers
WBC −.23 .02 −.22 .04
Fibrinogen −.32 .001 −.27 .009
hsCRP −.22 .03 −.15 .13
ESR −.26 .01 −.21 .03
Wellbeing
Vitality .30 .004 .20 .05
HADS depression −.18 .07 −.03 .81
HADS Anxiety −.02 .87 .12 .21
Global fatigue −.19 .054 −.03 .75
EuroQol .26 .01 .12 .24
HADS, hospital anxiety and depression scale; EuroQol, European assessment
for quality of life. All variables were corrected for gender. p value in bold
indicate statistical significance
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peak, Framingham risk score, WBC, CRP, ESR, fibrino-
gen, vitality, and EuroQol accounted for 29.7 % of the
variation in HRR1 (F (11, 67) = 2.57, p = .009, R2 = 0.29).
However, even though almost a third of the variance in
HRR1 was explained by these variables, none of the vari-
ables were independently associated with HRR1. For
HRR2, using the same method, a model which included
age, resting systolic blood pressure, triglycerides,
HOMA, VO2 peak, Framingham risk score, WBC, ESR,
fibrinogen and vitality accounted for 37.9 % of the vari-
ation in HRR2 (F (11, 65) = 3.6, p = .001, R2 = 0.37). Simi-
lar to HRR2, none of the variables were independently
associated with HRR2. Data was checked for collinearity,
but this revealed not to influence the data. Additionally,
in a different analyses, using age as a confounding factor
along with gender did not change the model presented
in Table 4 (data not reported).
Discussion
To our knowledge, this is the first study to assess the rela-
tionship between HRR and CVD risk factors, disease-
related measures and indicators of wellbeing in RA
patients. As expected, many CVD risk factors, inflamma-
tory markers and some measures of wellbeing were corre-
lated with HRR. However, multivariate analyses revealed
that the variance in HRR was explained by a group of fac-
tors including CVD risk factors, inflammatory markers
and some measures of wellbeing, but none of the variables
tested were independently associated with HRR. This may
suggest that it is the overall CVD risk and disease-related
burden that contributes to changes in HRR, instead of one
or several individual factors.
The current study is the first to reveal that HRR was
correlated with individual CVD risk factors in RA. In
line with other populations [53], an association was
found between triglycerides and HRR, which is not sur-
prising given the association between lipid metabolism
and the ANS [54]. As expected based on findings from
other populations [55], cardiorespiratory fitness was also
correlated with HRR, a phenomenon mainly attributed to
improved baroreflex sensitivity [56]. Moreover, our results
revealed that age was inversely associated with HRR which
is in line with some [30, 35], but not all studies [27, 31] in
this field. Similar equivocal findings have been found be-
tween autonomic function and body composition [24, 27].
The variation in findings of the available studies is prob-
ably due to the differences in the ANS assessment.
To our knowledge, this is the first study to report an
association between global CVD risk (FRS) and HRR in
RA. The effect size of the associations between global
CVD risk and HRR were greater than the effect sizes of
the associations between individual risk factors and
HRR. Given that FRS comprises of multiple variables,
this association, together with the finding that none of
the individual risk factors were independently associated
with HRR in multivariate analyses, suggests that rather
than individual risk factor, the overall RA- and CVD re-
lated burden is an important factor that associates with
parasympathetic function.
In line with cross-sectional and experimental studies
in other populations [14, 57], disease-related inflamma-
tion was inversely associated with HRR. In RA patients
however, the results are equivocal. As recently reviewed,
the majority of the studies do not find an association be-
tween inflammation or disease activity and autonomic
function in RA, even though there are some exceptions
[9]. For example, CRP [35], and leukocytes [34] were re-
ported to be related to autonomic dysfunction, but more
studies reported no such association [15, 19, 23, 24, 33].
Similar to inflammation, disease activity (DAS28) was
found to be associated with autonomic function in some
[20, 30, 34], but not all studies [15, 19, 23, 24, 31, 33].
Comparison between the different studies is difficult
given the different methods used to assess autonomic
function (i.e., heart rate variability (HRV) [36], pupillary
response to light [31], Ewing test [22], and HRR as in
the current study). When exploring the available studies
in more detail, it is worth noting that studies that re-
ported no association between autonomic function and
Table 4 Linear regression model for factors associated with
HRR1 and HRR2
HRR1 HRR2
Variable β t (p) β t (p)
Cardiovascular risk factors
Age −0.26 −1.25 (.21) −0.46 −1.91 (.06)
Triglycerides −21.69 −1.48 (.14) −6.03 −0.37 (.71)
VO2 peak 0.05 0.11 (.91) 0.45 −0.98 (.32)
Framingham risk score 0.09 0.01 (.99) −2.72 −0.25 (.79)
Resting SBPa −0.07 −0.69 (.48)
HOMAa −2.51 −0.16 (.86)
Inflammatory markers
WBC −0.57 −0.66 (.51) −0.01 −0.02 (.98)
Fibrinogen −3.18 −1.36 (.17) −2.24 −0.94 (.34)
hsCRPb 0.86 0.16 (.87)
ESR 4.49 0.70 (.48) 6.62 0.99 (.32)
Wellbeing
Vitality 1.27 0.98 (.32) 2.09 1.78 (.07)
EuroQolb 33.65 1.09 (.27)
R2 and p-value of the model R2 p R2 p
0.297 0.009 0.379 0.001
aIndicates variable that was not correlated with HRR1 in univariate analyses,
therefore, was not included in model 1
bIndicates variable that was not correlated with HRR2 in univariate analyses,
therefore, was not included in model 2
p value in bold indicate statistical significance
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inflammation used the Ewing test battery as a method of
assessment [15], whereas those who did report an asso-
ciation measured autonomic function using HRV [35].
The Ewing test battery consists of five separate assess-
ments with a dichotomized response to each test and
the total score is the sum of all the responses [58]. HRV
and HRR in contrast, use continuous heart rate readings
to derive a measure of autonomic function. Therefore, it
could be argued that statistically HRV and HRR are
more sensitive tests for exploring associations compared
to the Ewing test battery. However, without making a
direct comparison between factors associated with the
Ewing test battery and HRV or HRR in the same popula-
tion, this suggestion remains speculative.
There were subtle differences in the associations be-
tween inflammation and HRR1 and HRR2 in the current
study; CRP was associated with HRR1 which is related
to parasympathetic reactivation, but not HRR2, which is
reflective of sympathetic withdrawal [17]. Similarly, in-
ducing inflammation reduced HRR1 but not HRR2 in
healthy participants [14]. Interestingly, the evidence for
parasympathetic dysfunction is also more evident in RA
compared to sympathetic dysfunction [9]. From a theor-
etical standpoint, the association between inflammation
and the parasympathetic system is not unexpected. This
could be explained via the mechanism of cholinergic
anti-inflammatory pathway, where release of inflamma-
tory markers such as tumor necrosis factor alpha and
interleukin-1 is controlled by the vagus nerve which is
part of the parasympathetic system [59]. However, future
research is needed to explore this association in more
detail in patients with RA.
The first two minutes of HRR are the most vali-
dated [60] and commonly used method in studies,
and have been suggested to be a better predictor of
mortality and coronary artery disease (CAD) [61].
The subtle differences in the factors related with
HRR1 and HRR could perhaps be due to the different
aspects of ANS which are reflected by HRR1 and
HRR2: HRR1 is known to represent activation of
parasympathetic system, whereas, HRR2 represent ac-
tivation of parasympathetic and withdrawal of sympa-
thetic nervous system [62]. In the current study, SBP
and insulin resistance were significantly associated
with HRR2 but not HRR1. Interestingly, insulin has
been found to have a stimulatory effect on the sym-
pathetic nervous system [63], and metabolic risk fac-
tors have been more strongly related to HRR2 than
HRR1 in healthy participants. However, this complex
interaction between the two systems in controlling
post exercise HRR still needs further clarification.
To our knowledge, this is the first study to explore
associations between markers of psychological well-
being and autonomic function in RA. This is
surprising given that psychological factors have been
associated with CVD and autonomic function has
been implicated as an underlying pathway by which psy-
chological wellbeing contributes towards the pathogenesis
of CVD [64]. Indeed, history of anxiety and depression
[65], as well as emotional stress [66], have been asso-
ciated with lower parasympathetic activity. In the
current study, even though no significant relationship
was found between either depression or anxiety and
HRR, vitality and quality of life (EuroQol) were re-
lated to HRR. This may suggest that maintaining a
good quality of life and the perception of feeling en-
ergized and capable of doing tasks may favor a bal-
anced activity of the ANS.
There are number of limitations in this study. The
cross-sectional design does not allow for the assess-
ment of causality between variables. The current
study did not have a comparison group, however, as
the aim of the current study was to explore factors
associated with parasympathetic activity in RA, the
focus was specifically on RA patients. Without a con-
trol group, a direct comparison between parasympa-
thetic activity in RA and other populations is not
possible. Comparing HRR in this well-controlled co-
hort of RA patients from this study to HRR reported
in healthy participants in other studies [67, 68], reveal
similarities in parasympathetic function. Caution
should of course be taken when comparing different
studies as variations in the methods are likely to in-
fluence the findings. Therefore, future studies should
examine differences between HRR in RA and other
population as well as exploring factors associated with
HRR in other population. For ethical reasons, the pa-
tients did not discontinue their medication prior to
the assessments. As is common in this population,
the patients included in this study were on a mix of
medications, which means that we did not have an
appropriate statistical power to explore the influence
of medication on HRR. Further research should inves-
tigate the potential influence of medication on HRR
in patients with RA. The disease activity of most of
the RA patients involved in this study was well con-
trolled; therefore, it is difficult to generalize these
findings to RA patients with higher disease activity. It
is possible that patients were not able to exercise to
their maximum cardiorespiratory ability due to problems
with their joints, which could have influenced their HRR
[17]. However, based on respiratory exchange ratios (RER)
which reflect the amount of energy metabolized to provide
energy, we are confident that most of the participants in
our study were able to exercise until exhaustion. Future
research should also explore the association between CVD
risk, inflammation, and wellbeing with other measures of
ANS, such as HRV.
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Conclusions
In conclusion, the results of this study showed that CVD
risk, disease related inflammations, and wellbeing associ-
ate with HRR in RA. As there is ample evidence that
HRR is related to CVD mortality in other populations
[16], further research should explore if HRR is also pre-
dictive of hard CVD endpoints in RA. In addition, given
that exercise interventions can reduce CVD risk in RA
[69], and improve parasympathetic reactivation [70],
further research should also examine the effects of an
exercise intervention on HRR in this population. The
results of this study suggest that reducing CVD risk in
RA is likely to require interventions to improve classical
risk factors, inflammation, physical fitness, and psycho-
logical well-being. HRR could be used as an overall
marker of patients at risk of developing CVD, therefore,
can be used as a marker to see whether an intervention
is effective in this cohort. However, this will need further
research to investigate the effectiveness of an interven-
tion using HRR.
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